Clinical TrialsPreclinical results demonstrated SL-325 safety and feasibility of maintenance dosing, with a lead DR3 bispecific candidate nomination expected later this year.
Financial PerformanceThe announcement of 1Q25 results showed an EPS of ($0.27), which was better than both the analyst's estimate of ($0.40) and the consensus of ($0.28).
Preclinical DataPositive preclinical data for SL-325 was presented at the 20th Congress of ECCO in Inflammatory Bowel Diseases, highlighting its potential as a differentiated approach to current IBD treatments.